V Craig Jordan Selected Research

Estrogens (Estrogen)

06/2008	The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?
04/2008	Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
01/2007	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
01/2006	Estrogen-related receptors as emerging targets in cancer and metabolic disorders.
12/2005	Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
11/2005	Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells.
02/2005	Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
09/2004	The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.
05/2004	Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
03/2004	Selective estrogen receptor modulation: concept and consequences in cancer.
05/2003	Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.
08/2002	Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death.
08/2002	Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
01/2002	In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.

Articles by Research Topic

Disease

41	Breast Neoplasms (Breast Cancer) 06/2008 - 01/2002
8	Neoplasms (Cancer) 05/2008 - 02/2002
2	Endometrial Neoplasms (Endometrial Cancer) 09/2005 - 06/2002
2	Neoplasm Metastasis (Metastasis) 05/2005 - 05/2003

Drug/Important Bio-Agent (IBA)

16	Tamoxifen FDA LinkGeneric 11/2007 - 02/2002
14	Estrogens (Estrogen)FDA Link 06/2008 - 01/2002
7	Raloxifene (Evista)FDA Link 06/2008 - 02/2002
5	Selective Estrogen Receptor Modulators (SERM)IBA 12/2007 - 02/2002
5	Estrogen Receptor alphaIBA 09/2006 - 03/2002
4	Estrogen Receptor Modulators (Antiestrogen)IBA 09/2004 - 01/2002
3	Estrogen ReceptorsIBA 11/2007 - 03/2004
3	Estradiol (Estrace)FDA LinkGeneric 12/2005 - 08/2002
2	fulvestrant (Faslodex)FDA Link 02/2007 - 11/2003
2	resveratrolIBA 03/2004 - 05/2003
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2008
1	Steroid Receptors (Steroid Receptor)IBA 12/2006
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 09/2006
1	P-2 (P 2)IBA 06/2006
1	Biological Markers (Surrogate Marker)IBA 06/2006
1	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2005
1	trastuzumab (Herceptin)FDA Link 09/2005
1	Medroxyprogesterone 17-Acetate (Depo-Provera)FDA LinkGeneric 05/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 05/2004
1	Furylfuramide (AF2)IBA 03/2004
1	HormonesIBA 01/2003
1	SteroidsIBA 08/2002
1	3- (4- (1,2- diphenylbut- 1- enyl)phenyl)acrylic acidIBA 06/2002
1	Transforming Growth Factor alpha (TGF-alpha)IBA 03/2002
1	Aromatase InhibitorsIBA 02/2002
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2002

Therapy/Procedure

8	Chemoprevention 11/2007 - 01/2002
1	Drug Therapy (Chemotherapy) 05/2003